Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Targeting the aldosterone pathway in cardiovascular disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Protection against β adrenoceptor agonist reduction of plasma potassium in severe but not in moderate hypokalemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Strategy for clinical evaluation and screening of sudden cardiac death relatives

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sudden cardiac death--the challenge to cardiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. New strategies in insulin treatment: analogues and noninvasive routes of administration

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Finn Gustafsson
  • Michel Azizi
  • Johann Bauersachs
  • Frederic Jaisser
  • Patrick Rossignol
View graph of relations
Accumulated evidence has demonstrated that aldosterone is a key player in the pathogenesis of cardiovascular (CV) disease. Multiple clinical trials have documented that intervention in the aldosterone pathway can reduce blood pressure and lower albuminuria and improve outcome in patients with heart failure or myocardial infarction. Recent studies have unraveled details about the role of aldosterone at the cellular level in CV disease. The relative importance of glucocorticoids and aldosterone in terms of mineralocorticoid receptor activation is currently being debated. Also, studies are addressing which aldosterone modulator to use, which timing of treatment to aim for, and in which population to intervene. This review provides an overview of recent developments in the understanding of the role of aldosterone in CV disease, with particular reference to mechanisms and potential targets of intervention. Finally, ongoing or desirable clinical trials in the field are highlighted. The review is partly based on discussions between basic scientists and clinical trialists at the Cardiovascular Clinical Trials Forum 2009 and subsequently updated to encompass the most recent developments.
Original languageEnglish
JournalFundamental and Clinical Pharmacology
Volume26
Issue number1
Pages (from-to)135-45
Number of pages11
ISSN0767-3981
DOIs
Publication statusPublished - 2012

    Research areas

  • Aldosterone, Animals, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Drug Delivery Systems, Glucocorticoids, Humans, Receptors, Mineralocorticoid, Treatment Outcome

ID: 36843574